References/Publications for Nasal Test of Bet v 1

Check all              

Select PubMed ID Description
7684629 Int Arch Allergy Immunol. 1993;101(1):89-94.

Studies on the allergenicity of the amino-terminal epitope (Bet v I 23-38) from
birch pollen allergen.

Vik H(1), Steinvåg SK, Elsayed S.


9058691 J Allergy Clin Immunol. 1997 Mar;99(3):354-9.

Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity
reactions equal to those induced by natural Bet v 1 in the airways of patients
allergic to tree pollen.

Godnic-Cvar J(1), Susani M, Breiteneder H, Berger A, Havelec L, Waldhör T,
Hirschwehr R, Valenta R, Scheiner O, Rüdiger H, Kraft D, Ebner C.


10359907 J Allergy Clin Immunol. 1999 Jun;103(6):1202-10.

Suppression of antigen-specific T- and B-cell responses by intranasal or oral
administration of recombinant bet v 1, the major birch pollen allergen, in a
murine model of type I allergy.

Wiedermann U(1), Jahn-Schmid B, Bohle B, Repa A, Renz H, Kraft D, Ebner C.


11003446 Allergy. 2000 Sep;55(9):827-35.

Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II.
Side-effects.

Winther L(1), Malling HJ, Mosbech H.


16083789 J Allergy Clin Immunol. 2005 Aug;116(2):347-54.

Allergen-specific nasal IgG antibodies induced by vaccination with genetically
modified allergens are associated with reduced nasal allergen sensitivity.

Reisinger J(1), Horak F, Pauli G, van Hage M, Cromwell O, König F, Valenta R,
Niederberger V.


17204315 J Allergy Clin Immunol. 2007 Apr;119(4):937-43. Epub 2007 Jan 3.

Successful sublingual immunotherapy with birch pollen has limited effects on
concomitant food allergy to apple and the immune response to the Bet v 1 homolog
Mal d 1.

Kinaciyan T(1), Jahn-Schmid B, Radakovics A, Zwölfer B, Schreiber C, Francis JN,
Ebner C, Bohle B.


18241932 Immunol Lett. 2008 Apr 15;117(1):50-6. doi: 10.1016/j.imlet.2007.11.025. Epub
2007 Dec 31.

Susceptibility to nasal and oral tolerance induction to the major birch pollen
allergen Bet v 1 is not dependent on the presence of the microflora.

Repa A(1), Kozakova H, Hudcovic T, Stepankova R, Hrncir T, Tlaskalova-Hogenova H,
Pollak A, Wiedermann U.


18564326 Clin Exp Allergy. 2008 Sep;38(9):1514-25. doi: 10.1111/j.1365-2222.2008.03042.x.
Epub 2008 Jun 28.

Clinical effects of immunotherapy with genetically modified recombinant birch
pollen Bet v 1 derivatives.

Purohit A(1), Niederberger V, Kronqvist M, Horak F, Grönneberg R, Suck R, Weber
B, Fiebig H, van Hage M, Pauli G, Valenta R, Cromwell O.